Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Zura Bio Limited
Zura Bio Announces Robert Lisicki as CEO and Director
April 08, 2024
From
Zura Bio Limited
Via
Business Wire
Tickers
ZURA
Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer
March 28, 2024
From
Zura Bio Limited
Via
Business Wire
Tickers
ZURA
Zura Bio Announces Participation at March Conferences
March 04, 2024
From
Zura Bio Limited
Via
Business Wire
Tickers
ZURA
Zura Bio Announces Participation at February Investor Conferences
February 02, 2024
From
Zura Bio Limited
Via
Business Wire
Tickers
ZURA
Zura Bio Continues to Strengthen Leadership with Appointment of Robert Lisicki as President and Kiran Nistala as CMO
January 08, 2024
From
Zura Bio Limited
Via
Business Wire
Tickers
ZURA
Zura Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Dermatology Summit
January 03, 2024
From
Zura Bio Limited
Via
Business Wire
Tickers
ZURA
Zura Bio Announces Two Immunology Abstracts Presented at the World Allergy Congress in Bangkok
December 04, 2023
From
Zura Bio Limited
Via
Business Wire
Tickers
ZURA
Zura Bio Appoints Arnout Ploos van Amstel to its Board of Directors
November 14, 2023
From
Zura Bio Limited
Via
Business Wire
Tickers
ZURA
Zura Bio Reports Third Quarter 2023 Financial Results and Recent Business Highlights
November 13, 2023
From
Zura Bio Limited
Via
Business Wire
Tickers
ZURA
Zura Bio Enters into Sponsored Research Agreement with Benaroya Research Institute
September 12, 2023
From
Zura Bio Limited
Via
Business Wire
Tickers
ZURA
Zura Bio Reports Second Quarter 2023 Financial Results and Recent Business Highlights
August 14, 2023
From
Zura Bio Limited
Via
Business Wire
Tickers
ZURA
Zura Bio to Join the Russell 2000® and Russell 3000® Indexes
June 23, 2023
From
Zura Bio Limited
Via
Business Wire
Tickers
ZURA
Zura Bio Announces $80 Million Financing and the Licensing of Tibulizumab (ZB-106), a Potential First-in-Class anti-IL-17 and anti-BAFF Dual Antagonist for Autoimmune Diseases
April 27, 2023
From
Zura Bio Limited
Via
Business Wire
Tickers
ZURA
Zura Bio Announces Appointment of Chief Scientific Officer
April 14, 2023
From
Zura Bio Limited
Via
Business Wire
Tickers
ZURA
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.